Новые подходы к терапии нефропатий, ассоциированных с метаболическим синдромом: фокус на липидный профиль и адипокины: ОРИГИНАЛЬНЫЕ СТАТЬИ

Алина Алексеевна  Шевандова; Лея Евгеньевна  Сорокина; Ирина Ивановна  Фомочкина; Антон Владиславович  Ткач; Андрей Николаевич  Глушенков; Инна Владимировна  Черноусова; Михаил Эдуардович  Бычков

doi:10.56871/PED.2025.38.89.004

New approaches to treatment of metabolic syndrome — associated nephropathies: focus at lipid profile and adipokines

ORIGINAL STUDIES

Alina A. Shevandova Order of the Red Banner of Labor Medical Institute named after S.I. Georgievsky, Vernadsky Crimean Federal University, Simferopol, Russia
Leya E. Sorokina Order of the Red Banner of Labor Medical Institute named after S.I. Georgievsky, Vernadsky Crimean Federal University, Simferopol, Russia
Irina I. Fomochkina Order of the Red Banner of Labor Medical Institute named after S.I. Georgievsky, Vernadsky Crimean Federal University, Simferopol, Russia
Anton V. Tkach Order of the Red Banner of Labor Medical Institute named after S.I. Georgievsky, Vernadsky Crimean Federal University, Simferopol, Russia
Andrey N. Glushenkov Vernadsky Crimean Federal University, Physics and Technology Institute, Simferopol, Russia
Inna V. Chernousova NRC “Kurchatov Institute” — “Magarach”, Yalta, Russia
Mikhail E. Bychkov Order of the Red Banner of Labor Medical Institute named after S.I. Georgievsky, Vernadsky Crimean Federal University, Simferopol, Russia

Keywords:

метаболический синдром хроническая болезнь почек полифенольные концентраты нефропротективная терапия metabolic syndrome chronic kidney disease polyphenol concentrates nephroprotective therapy

Abstract

Background. Due to the increasing burden of metabolic diseases, the search for and development of pathogenetically sound and safe therapeutic strategies that influence the development and progression of nephropathy associated with metabolic syndrome is urgent.

Aim. To conduct a comparative evaluation of the effectiveness of various groups of drugs in correcting the metabolic profile and adipokine status to slow the progression of nephropathy associated with metabolic syndrome.

Materials and methods. An experimental study was conducted on Wistar rats. To simulate metabolic nephropathy, the animals were fed a solid diet containing 60% fructose. From weeks 14 to 24, the animals were administered various therapeutic compositions. At the end of the experiment, anthropometry of the animals was performed, and lipid metabolism parameters and blood adipokine levels were assessed.

Results. Results of multiple comparisons revealed no significant differences in cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, or leptin and adiponectin levels between the groups of animals receiving corrective therapy and the metabolic syndrome group without correction. However, a positive effect on lipid status and adipokine parameters was observed with monotherapy with a dipeptidyl peptidase 4 inhibitor and grape seed concentrate.

Conclusions. The positive trends observed in normalizing adipose tissue metabolic activity with the dipeptidyl peptidase 4 inhibitor and grape seed concentrate indicate their potential in the combination therapy of nephropathies associated with metabolic syndrome. However, further clinical trials are required to confirm their efficacy and safety.

References

Вербовой А.Ф., Вербовая Н.И., Долгих Ю.А. Ожирение — основа метаболического синдрома. Ожирение и метаболизм. 2021;18(2):142–149. https://doi.org/10.14341/omet12707.

Гоголева С.П., Аметов А.С., Черникова Н.А., Шабалина А.А., Антонова К.В., Хайкина М.Б., Черницкая Е.Р., Кушнир Н.В., Сташевская В.Н. Динамика показателей липидного обмена на фоне терапии дапаглифлозином у пациентов с сахарным диабетом 2-го типа. Лечебное дело. 2023;(4):32–37. https://doi.org/10.24412/2071-5315-2023-13023.

Трубицына Н.П., Шамхалова М.Ш., Шишкова Ю.А., Дроздова Е.Н., Никанкина Л.В., Ильин А.В., Кацая Г.В., Гончаров Н.П., Деев А.Д., Шестакова М.В. Феномен частичного ускользания блокады ангиотензина II у больных сахарным диабетом 2 типа с диабетической нефропатией при длительном применении ингибиторов АПФ. Нефрология и диализ. 2007;9(3):348–349.

Aoki K., Ijima T., Kamiyama H. et al. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study. Expert Opin Pharmacother. 2015;16(12):1749–1754. https://doi.org/10.1517/14656566.2015.1057120.

Briand F., Mayoux E., Brousseau E., Burr N., Urbain I., Costard C., Mark M., Sulpice T. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases ldl cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65(7):2032–2038. https://doi.org/10.2337/db16-0049.

de Araújo F.F., de Paulo Farias D., Neri-Numa I.A. et al. Polyphenols and their applications: An approach in food chemistry and innovation potential. Food Chem. 2021;338:127535. https://doi.org/10.1016/j.foodchem.2020.127535.

Feldman F., Koudoufio M., Desjardins Y., Spahis S., Delvin E., Levy E. Efficacy of polyphenols in the management of dyslipidemia: a focus on clinical studies. Nutrients. 2021;13(2):672. https://doi.org/10.3390/nu13020672.

Guerreiro Í., Ferreira-Pêgo C., Carregosa, D., Santos C.N., Menezes R., Fernandes A. S., Costa J.G. Polyphenols and their metabolites in renal diseases: an overview. Foods. 2022;11(7):1060. https://doi.org/10.3390/foods11071060.

Hass A., Oz H., Mashavi M., Shargorodsky M. Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients. J Am Soc Hypertens. 2014;8(10):709–714. https://doi.org/10.1016/j.jash.2014.07.033.

Hill N.R., Fatoba S.T., Oke J.L. et al. Global prevalence of chronic kidney disease — a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. https://doi.org/10.1371/journal.pone.0158765.

Kitamura N., Takahashi Y., Yamadate S. Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol. 2007;6:26–31. https://doi.org/10.1186/1475-2840-6-26.

Kovesdy C.P. Epidemiology of chronickidney disease: an update 2022. Kidney Int Suppl. 2022;12(1): 7–11. https://doi.org/10.1016/j.kisu.2021.11.003.

Kurella M., Lo J.C., Chertow G.M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16(7):2134–2140. https://doi.org/10.1681/ASN.2005010106.

Masaomi N., Yuko I., Nobuteru U. In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxida- tive/carbonyl stress and prevents diabetic nephropathy. Nephrol Dial Transplant. 2005;20(12):2661–2669. https://doi.org/10.1093/ndt/gfi096.

Ohishi T., Fukutomi R., Shoji Y. et al. The beneficial effects of principal polyphenols from green tea, coffee, wine, and curry on obesity. Molecules. 2021;26(2):453. https://doi.org/10.3390/molecules26020453.

Raikou V.D., Gavriil S. Metabolic syndrome and chronic renal disease. Diseases. 2018;6(1):12. https://doi.org/10.3390/diseases6010012.

Shin M.-R., Kim M.J., Park H.J., Han J., Roh S.S. Beneficial effect of Taraxacum coreanum nakai via the activation of LKB1-AMPK signaling pathway on obesity. Evid Based Complement Altern Med. 2021;2021:6655599. https://doi.org/10.1155/2021/6655599.

Suh J.H., Wang Y., Ho C.-T. Natural dietary products and their effects on appetite control. J Agric Food Chem. 2018;66(1):36–39. https://doi.org/10.1021/acs.jafc.7b05104.

Yano W., Inoue N., Ito S., Itou T., Yasumura M., Yoshinaka Y., Hagita S., Goto M., Nakagawa T., Inoue K., Tanabe S., Kaku K. Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice. J Diabetes Investig. 2017;8(2):155–160. https://doi.org/10.1111/jdi.12593.

Yu J.Z., Kalantar-Zadeh K., Rhee C.M. Adiponectin and leptin in kidney disease patients. Springer, Cham. 2019;1:277–290. https://doi.org/10.1007/978-3-319-97765-2_20.